1. Scrip
  2. >>Business
  3. >>Strategy

Can Organovo Leverage Its Solid Phase II Data In MASH?

 
• By Joseph Haas

Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.

Young woman suffering from itching on her skin and scratching an itchy place. Allergic reaction to insect bites, dermatitis, food, drugs. Health care concept. Allergy rash - Image
Organovo's candidate shows better pruritus data than others in its class.

The idea of an FXR agonist being the solution for treating metabolic function-associated steatohepatitis (MASH) took a substantial hit when Intercept Pharmaceuticals, Inc. ended development of obeticholic acid (OCA) in the disease. However, Organovo Holdings, Inc. has now reported Phase II data for an FXR agonist that shows hepatic fat-reducing ability as well as a cleaner safety and tolerability profile than typically seen with the drug class.

Key Takeaways

  • Organovo, which uses its bioprinting capabilities to produce 3D disease models, reported Phase II data in MASH that looks competitive compared to other FXR agonists.

Previously focused on bioprinting, research tools and tissue for direct therapy, Organovo in recent years has used its ability to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.